REHOVOT, Israel, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology
company developing novel products for life science markets, announced today that it will release its financial results for the
third quarter of 2018 on Wednesday, November 14, 2018.
On the day of the announcement, the Company’s management will host a conference call to discuss the results at
09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United
States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company’s
website at www.evogene.com.
A replay of the conference call will be available approximately three hours following the completion of the
call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5901 internationally. The
replay will be accessible through November 16, 2018, and an archive of the webcast will be available on the Company’s website
through November 18, 2018.
About Evogene:
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science
markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings
and advanced computational technologies. This platform is utilized by the Company to discover and develop innovative ag-chemical,
ag-biological and ag-seed products (GM and non-GM), and by two subsidiaries; Evofuel, focused on castor seeds, and Biomica, focused
on human microbiome therapeutics. Through its collaborations with world-leading agricultural companies such as BASF, Corteva, Bayer
and ICL, Evogene has licensed genes, small molecules and microbes to partners under milestone and royalty bearing agreements. For
more information, please visit www.evogene.com
Forward Looking Statements
This press release contains "forward-looking statements" relating to future
events. These statements may be identified by words such as "may", "could",
“expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar
meaning. Such statements are based on current expectations, estimates, projections and assumptions,
describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and
are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ
materially from what is expressed or implied by such forward-looking statements due to a variety of
factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in
Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to
update these forward-looking statements to reflect future events or developments or changes in expectations, estimates,
projections and assumptions.
Evogene Investor Contact:
Nir Zalik
IR Director
IR@evogene.com
972-8-931-1900
US Investor Relations:
Vivian Cervantes
PCG Investor Relations
vivian@pcgadvisory.com
646-863-6274
